Compositions and methods for the therapy and diagnosis of influenza
AssigneeTheraclone Sciences, Inc.
InventorsAndres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
Life of this patent
Estimating the term…
Abstract
The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.
Claims21
A human monoclonal antibody that specifically binds to an epitope in the extracellular domain of the matrix 2 ectodomain (M2e) polypeptide of an influenza virus wherein said monoclonal antibody is 3241_G23, 3244_I10, 3243_J07, 3259_J21, 3245_O19, 3244_H04, 3136_G05, 3252_C13, 3255_J06, 3420_I23, 3139_P23, 3248_P18, 3253_P10, 3260_D19, 3362_B11, or 3242_P05.
An isolated anti-matrix 2 ectodomain (M2e) antibody, or antigen-binding fragment thereof, comprising a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain and the VL domain each comprise three complementarity determining regions 1 to 3 (CDR1-3), and wherein each CDR comprises the following amino acid sequences:
- VH CDR1:
- SEQ ID NOs:
- 179, 187, 196, 204, 212, 224, 314, 235, 242, 248, or 254;
- VH CDR2:
- SEQ ID NOs:
- 180, 188, 195, 197, 205, 213, 218, 225, 231, 236, 243, 249, 246, or 256;
- VH CDR3SEQ ID NOs:
- 181, 189, 198, 206, 214, 219, 226, 232, 237, 244, or 250;
- VL CDR1:
- SEQ ID NOs:
- 184, 192, 199, 215, 220, 233, or 238;
- VL CDR2:
- SEQ ID NOs:
- 61, 185, 193, 200, 207, 211, 216, 227, 239, or 241;
- and
- VL CDR3:
- SEQ ID NOs:
- 63, 186, 194, 201, 208, 221, 228, 234, 240, 245, or 251.
An isolated anti-matrix 2 ectodomain (M2e) antibody, or antigen-binding fragment thereof, comprising a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain and the VL domain each comprise three complementarity determining regions 1 to 3 (CDR1-3), and wherein each CDR comprises the following amino acid sequences:
- VH CDR1:
- SEQ ID NOs:
- 182, 190, 202, 209, 222, 229, 247, 252, 257, 258, or 260;
- VH CDR2:
- SEQ ID NOs:
- 183, 191, 203, 210, 217, 223, 230, 246, 253, 259, or 261;
- VH CDR3SEQ ID NOs:
- 181, 189, 195, 198, 206, 214, 219, 226, 232, 237, 244, or 250;
- VL CDR1:
- SEQ ID NOs:
- 184, 192, 199, 215, 220, 233, or 238;
- VL CDR2:
- SEQ ID NOs:
- 61, 185, 193, 200, 207, 211, 216, 227, 239, or 241;
- and
- VL CDR3:
- SEQ ID NOs:
- 63, 186, 194, 201, 208, 221, 228, 234, 240, 245, or 251.
An antibody that binds the same epitope as monoclonal antibody 3241_G23, 3244_I10, 3243_J07, 3259_J21, 3245_O19, 3244_H04, 3136_G05, 3252_C13, 3255_J06, 3420_I23, 3139_P23, 3248_P18, 3253_P10, 3260_D19, 3362_B11, or 3242_P05.
An isolated fully human monoclonal anti-matrix 2 ectodomain (M2e) antibody comprising:
- a) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO:
- 44 and a light chain sequence comprising amino acid sequence SEQ ID NO:
- 46;
- b) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO:
- 319 and a light chain sequence comprising amino acid sequence SEQ ID NO:
- 46;
- c) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO:
- 321 and a light chain sequence comprising amino acid sequence SEQ ID NO:
- 46;
- d) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO:
- 50 and a light chain sequence comprising amino acid sequence SEQ ID NO:
- 52;
- e) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO:
- 323 and a light chain sequence comprising amino acid sequence SEQ ID NO:
- 52;
- or
- f) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO:
- 325 and a light chain sequence comprising amino acid sequence SEQ ID NO:
- 52.
Dependencies are inferred from the claim text.